The authors like to thank Lewis Mervin (Centre for Molecular Informatics, Department of Chemistry, University of Cambridge) for his insightful comments and for reviewing the manuscript. Authorship Contribution Qurrat Ain, Andreas Bender, David Pryde, Robert Participated in research design: Owen, Kiyoyuki Omoto and Krishna C Bulusu Qurrat Ain and Julian Fuchs Conducted experiments: Qurrat Ain, Julian Fuchs, Rubben Torella Performed Analysis: Qurrat Ain, Andreas Bender, David Pryde, Wrote and contributed to manuscript: Robert Owen and Kiyoyuki Omoto, Julian Fuchs, Rubben Torella and Robert Glen. Abdi H, and Williams LJ (2010) Principal component analysis. Wiley Interdiscip Rev 2:433–459. Comput Stat Atack JR (2010) Development of Subtype-Selective GABAA Receptor Compounds for (Monti JM ed), Springer. the Treatment of Anxiety, Sleep Disorders and Epilepsy Atack JR (2008) GABAA Receptor Subtype-Selective Efficacy: TPA023, an α2/α3 Selective Non-sedating Anxiolytic and an Selective Cognition α5IA, α5 Enhancer. 14:25–35. CNS Drug Rev Atack JR (2011a) GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. 11:1176–202. Curr Top Med Chem Atack JR (2011b) GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. 11:1203–1214. Curr Top Med Chem Atack JR (2009) Subtype-selective GABA(A) receptor modulation yields a novel Edition, pharmacological profile: the design and development of TPA023., Elsevier. Atack JR (2005) The benzodiazepine binding site of GABA(A) receptors as a target
The authors like to thank Lewis Mervin (Centre for Molecular Informatics, Department of Chemistry, University of Cambridge) for his insightful comments and for reviewing the manuscript. Authorship Contribution Participated in research design: Qurrat Ain, Andreas Bender, David Pryde, Robert Owen, Kiyoyuki Omoto and Krishna C Bulusu Conducted experiments: Qurrat Ain and Julian Fuchs Performed Analysis: Qurrat Ain, Julian Fuchs, Rubben Torella Wrote and contributed to manuscript: Qurrat Ain, Andreas Bender, David Pryde, Robert Owen and Kiyoyuki Omoto, Julian Fuchs, Rubben Torella and Robert Glen. Abdi H, and Williams LJ (2010) Principal component analysis. Wiley Interdiscip Rev Comput Stat 2:433–459. Atack JR (2010) Development of Subtype-Selective GABAA Receptor Compounds for the Treatment of Anxiety, Sleep Disorders and Epilepsy (Monti JM ed), Springer. Atack JR (2008) GABAA Receptor Subtype-Selective Efficacy: TPA023, an α2/α3 Selective Non-sedating Anxiolytic and α5IA, an α5 Selective Cognition Enhancer. CNS Drug Rev 14:25–35. Atack JR (2011a) GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem 11:1176–202. Atack JR (2011b) GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Curr Top Med Chem 11:1203–1214. Atack JR (2009) Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023., Edition, Elsevier. Atack JR (2005) The benzodiazepine binding site of GABA(A) receptors as a target
GABA_final.docx